Stryker Corporation

New York Stock Exchange
Back to all articles
Very Bullish +80

Stryker closes Amplitude Vascular acquisition - MedTech Dive

📰 Stryker has officially completed its acquisition of Amplitude Vascular Systems, finalizing the deal less than a month after it was initially announced.

💸 The financial terms of the acquisition were not disclosed in the report.

🩺 Amplitude's primary technology is the Pulse intravascular lithotripsy (IVL) platform, designed to treat severely calcified arterial disease using pressure waves.

🔬 The IVL device utilizes carbon dioxide to generate pressure waves delivered through a balloon catheter to fracture calcium and expand narrowed vessels.

🚀 This acquisition allows Stryker to enter the booming intravascular lithotripsy market, which has attracted major investment from competitors like Johnson & Johnson, Boston Scientific, and Abbott.

🔄 Stryker stated that adding this IVL platform will strengthen its peripheral vascular portfolio, building on the Inari Medical clot-removal business acquired for $4.9 billion last year.

🧠 CEO Kevin Lobo confirmed on an earnings call that Stryker expects to remain active in mergers and acquisitions through the end of 2025 and into 2027.

💰 The company emphasized it has sufficient cash reserves in its pipeline to execute additional deals, signaling continued aggressive growth strategy.

⚖️ Johnson & Johnson previously made the industry's biggest acquisition in 2024 by purchasing Shockwave Medical for $13.1 billion to enter the IVL space.

📈 Boston Scientific also moved into the market last year with the acquisition of Bolt Medical, paying up to $664 million for its remaining stake.

🏥 Abbott approved its IVL clinical trial in the U.S. in 2025 following its 2023 acquisition of Cardiovascular Systems for $890 million.

🧪 Amplitude began enrolling patients in a pivotal U.S. IVL study in 2024, focusing on treating coronary and carotid disease.

💹 In January 2025, Amplitude raised $36 million to support device launch and further U.S. trials for calcified artery treatments.

🔍 The technology specifically targets peripheral artery disease and coronary artery disease where vessel narrowing reduces blood flow to limbs.

📅 All reported financial transactions and regulatory approvals mentioned are tied to fiscal years or specific dates up through early 2025.

Bullish Signals
  • Stryker has successfully completed the acquisition of Amplitude Vascular Systems, rapidly closing the deal less than a month after the announcement.
  • The acquisition gives Stryker access to the booming intravascular lithotripsy (IVL) market, which has already attracted major investments from industry leaders like Johnson & Johnson, Boston Scientific, and Abbott.
  • Stryker signaled strong financial confidence by maintaining an active M&A pipeline through 2027, with CEO Kevin Lobo confirming the company has sufficient cash to execute further deals.
  • The Pulse platform acquired is designed for severe calcified arterial disease, a critical unmet need where competitors like Johnson & Johnson paid $13.1 billion for Shockwave Medical in 2024.
  • Amplitude raised $36 million in January 2025 to support device launches and U.S. clinical trials, demonstrating strong investor confidence in the technology's potential to treat coronary and carotid disease.
  • Stryker expands its peripheral vascular portfolio with a leading-edge lithotripsy solution, complementing its recent $4.9 billion acquisition of Inari Medical for clot removal.
Risk Factors
  • Competitors like Johnson & Johnson, Boston Scientific, and Abbott are aggressively pursuing the intravascular lithotripsy (IVL) market with multi-billion dollar acquisitions (e.g., J&J's $13.1 billion purchase of Shockwave Medical, Abbott's $890 million acquisition of Cardiovascular Systems), intensifying competition.
  • The financial terms for Stryker's Amplitude Vascular acquisition were not disclosed, leaving investors uncertain about the deal's cost and potential impact on future earnings.
  • Stryker plans to remain active in M&A activity through 2027, which may signal an over-extension of resources or a reliance on acquisitions rather than organic growth to drive value.
  • The competitive landscape suggests that other major players are consolidating rapidly, potentially squeezing margins for smaller entrants like the acquired Amplitude Vascular Systems in the long term.
  • Amplitude Vascular Systems recently raised $36 million in January 2025 to support U.S. trials, indicating the high capital requirements and risk profile associated with bringing new IVL technologies to market.
Full Analysis
Stryker Corporation has officially completed the acquisition of Amplitude Vascular Systems, a deal aimed at expanding its presence in the intravascular lithotripsy (IVL) market. This platform, known as the Pulse, utilizes pressure waves generated by carbon dioxide delivered through a balloon catheter to fracture calcified plaque in narrowed arteries, thereby restoring blood flow in both coronary and peripheral vessels. The transaction was finalized less than a month after it was announced, though specific financial terms were not disclosed. This acquisition allows Stryker to bolster its peripheral vascular portfolio, which already includes the clot-removal business acquired from Inari Medical for approximately $4.9 billion last year. The move aligns Stryker with other major industry players, including Johnson & Johnson, Boston Scientific, and Abbott, who have recently made significant investments or acquisitions in the IVL space to address severely calcified arterial disease. Notably, J&J's acquisition of Shockwave Medical for $13.1 billion last year stands as the industry's largest deal of 2024. Stryker CEO Kevin Lobo confirmed the company's continued focus on mergers and acquisitions, stating that they possess sufficient cash reserves to pursue further deals through the end of the current year and into 2027. He highlighted an active pipeline and expressed investor confidence in their M&A strategy for the upcoming period. Meanwhile, Amplitude Vascular began enrolling patients in a pivotal U.S. study in 2024 and raised $36 million in January 2025 to support device launch and clinical trials for treating coronary and carotid disease. The integration of this technology is expected to strengthen Stryker's competitive position against rivals actively seeking approvals and market entry in the growing IVL sector.